In contrast, moderate or high levels of FASN (immunoreactivity score of ≥3) were observed in 22 of 38 NPC tumors (58%) (Figure 5A, representative NPC: T13, T22, and T34). This evidence concerns the gene FASN and nasopharyngeal carcinoma.